Novavax Ready to Produce Nearly 3 Billion Coronavirus Vaccine Doses (With a Little Help From Friends)

Novavax Ready to Produce Nearly 3 Billion Coronavirus Vaccine Doses (With a Little Help From Friends)

Novavax (NASDAQ: NVAX) has only completed the first phase of clinical trials for its coronavirus vaccine, NVX-CoV2373, but the relatively small biotech has already lined up at least 2.75 billion in manufacturing capacity through partnerships and an acquisition.